Grayscale’s Dogecoin and XRP exchange-traded funds have been cleared for listing on the New York Stock Exchange and are expected to debut later today. NYSE Arca, a subsidiary of the exchange, filed and disclosed two separate certifications with the Securities…Grayscale’s Dogecoin and XRP exchange-traded funds have been cleared for listing on the New York Stock Exchange and are expected to debut later today. NYSE Arca, a subsidiary of the exchange, filed and disclosed two separate certifications with the Securities…

Grayscale’s Dogecoin and XRP ETFs approved for NYSE listing later today

2025/11/24 13:37
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Grayscale’s Dogecoin and XRP exchange-traded funds have been cleared for listing on the New York Stock Exchange and are expected to debut later today.

Summary
  • NYSE Arca secured regulatory signoff to list Grayscale’s new XRP (GXRP) and Dogecoin spot ETFs (GDOGE).
  • ETF analyst Eric Balchunas expects GDOG to generate trading volumes of around $11 million on its first day.

NYSE Arca, a subsidiary of the exchange, filed and disclosed two separate certifications with the Securities and Exchange Commission on November 21 to confirm its “approval for listing and registration” of the Grayscale XRP Trust ETF Shares (GXRP) and the Grayscale Dogecoin Trust ETF Shares (GDOG).

For those unaware, Grayscale’s GXRP fund will offer direct exposure to the price of XRP, while GDOG tracks the spot price of Dogecoin. Through this structure, investors are able to gain regulated access to these cryptocurrencies without having to hold the underlying assets themselves. Both ETFs operate as spot products, meaning they hold actual XRP and DOGE in custody.

Market analysts, meanwhile, are already setting expectations for the next wave of altcoin ETF listings, and according to Bloomberg’s ETF analyst Eric Balchunas, Grayscale’s Chainlink ETF may be next in line.

“GLNK coming soon as well, week after I think,” Balchunas wrote in a Sunday X post about today’s launch.

Responding to one of his followers regarding his expectations for how these funds may perform on day one, Balchunas said he expects multi-million dollar trading volumes for GDOG.

“Initial guess maybe $11 million. But will ponder more,” he said.

Altcoins ETFs impress at launch

Over the past few weeks, a number of altcoin-focused ETFs, including those tied to XRP, Solana, Litecoin, and HBAR, have surfaced thanks to updated SEC legislation that fast-tracked approvals, which were once delayed by procedural red tape.

Late last month, Bitwise launched its Solana ETF, which began trading alongside Canary Capital’s Litecoin and HBAR funds. In the weeks since, new filings and launches from issuers like Franklin Templeton, 21Shares, and Bitwise have rapidly entered the market.

Most of these ETFs have witnessed solid day-one numbers, with Bitwise’s Solana fund posting nearly $70 million in net inflows at the launch day close, while Canary’s XRP ETF recorded over $250 million when first-day trading ended.

For Grayscale’s GXRP and GDOG ETFs, however, the launch day may be more muted, as the overall crypto market remains in peril. Bitcoin continues to sink below multi-month lows and is giving back most of the gains it posted earlier in the year.

As previously reported by crypto.news, ETF funds from Grayscale and BlackRock have led the recent wave of outflows, as investors continue to pull out funds in what appears to be widespread year-end profit taking and risk-off repositioning.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3665
$1.3665$1.3665
+0.73%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09